{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-027642","form_type":"8-K","ticker":"EVFM","cik":"0001618835","company_name":"Evofem Biosciences, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.579908+00:00","generated_at":"2026-06-11T17:43:46.474203+00:00","sec_items":["1.01","5.03","5.07","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Evofem raises $650K net via $1M convertible note offering and debt-for-preferred exchange","bullets":["Issued $1M in senior subordinated convertible notes at 8% interest, convertible at $1.25/share; net proceeds ~$650K.","Warrants to purchase 799,999 shares at $1.25/share, with price adjustment clauses; expire in 5 years.","Exchanged $1.8M in existing senior secured notes for 1,800 shares of Series E-1 preferred stock, convertible at $0.40/share.","Annual meeting scheduled for Sept 14, 2023; proposals include director election, exec comp vote, and share increase to 1.2B."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-027642","json":"https://secwatch.observer/filing/0001493152-23-027642.json","markdown":"https://secwatch.observer/filing/0001493152-23-027642.md","text":"https://secwatch.observer/filing/0001493152-23-027642.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223027642/0001493152-23-027642-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223027642/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T17:43:46.474203+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4a2d96352ffb1bfb0731e1d9ad7539c6432c980f","claim":"Evofem Biosciences, Inc.: Filed Certificate of Designations creating Series E-1 Preferred Stock, part of Amended and Restated Articles of Incorporation (effective 2023-08-07).","evidence_excerpt":"On August 7, 2023 the Company filed the Certificate of Designations creating the Series E-1 Preferred Stock. The Certificate of Designations, which forms a part of the Company’s Amended and Restated Articles of Incorporation, specifies the terms of the Series E-1 Preferred Stock.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223027642/0001493152-23-027642-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-08-07"}],"fact_type":"governance_change"},{"claim_id":"b1787cd4ed3e14cb98748c07d2c07e2e63ed7ec8","claim":"Evofem Biosciences, Inc. entered into Securities Purchase Agreement with certain investors valued at Notes in aggregate original principal amount of $1,000,000 and Warrants to purchase 799,999 shares o (effective 2023-08-04).","evidence_excerpt":"On August 4, 2023, Evofem Biosciences, Inc., a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (“ SPA ”), with certain investors (the “ Investors ”) providing for the sale and issuance of senior subordinate convertible notes due in the aggregate original principal amount of $1,000,000 (the “ Notes ”) and warrants (“ Warrants ”) to purchase an aggregate 799,999 shares of Common Stock, par value $0.0001 per share (the “ Common Stock ”) (collectively, the “ Offering ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223027642/0001493152-23-027642-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"certain investors"},{"label":"Value","value":"Notes in aggregate original principal amount of $1,000,000 and Warrants to purchase 799,999 shares o"},{"label":"Effective","value":"2023-08-04"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}